Simultaneous determination of blonanserin and its four metabolites in human plasma using ultra-performance liquid chromatography–tandem mass spectrometry
Authors:
- Ming LiuMLMing Liu
- Ji JiangJJJi Jiang
- Hongyun WangHWHongyun Wang
- Pei HuPHPei Hu
- 1 November 2013
- journal article
- Published by Elsevier in Journal of Chromatography B
- Vol. 939, 59-66
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic studyJournal of Chromatography B, 2012
- Sensitive Analysis of Blonanserin, a Novel Antipsychotic Agent, in Human Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass SpectrometryAnalytical Sciences, 2010
- Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonistPharmacology Biochemistry and Behavior, 2010
- Efficacy and Tolerability of Blonanserin in the Patients With SchizophreniaClinical Neuropharmacology, 2010
- Simple analysis of blonanserin, a novel antipsychotic agent, in human plasma by GC-MSForensic Toxicology, 2010
- Pharmacological profiles and clinical effects of blonanserin (Lonasen®) on schizophreniaFolia Pharmacologica Japonica, 2008
- Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agentBioorganic & Medicinal Chemistry Letters, 2005
- Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?Rapid Communications in Mass Spectrometry, 2005
- Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in miceNeuroReport, 2003
- Determination of a novel anti-psychotic agent AD-5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detectionJournal of Pharmaceutical and Biomedical Analysis, 1997